Ruxolitinib-associated infections: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Ruxolitinib-associated infections: A systematic review and meta-analysis

Published:2017-12-04 Issue:3 Volume:93 Page:339-347
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Lussana Federico¹^ORCID,Cattaneo Marco²,Rambaldi Alessandro¹³,Squizzato Alessandro⁴

Affiliation:

1. Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XIII; Bergamo Italy

2. Medicina III, Ospedale San Paolo, ASST Santi Paolo e Carlo Dipartimento di Scienze della Salute; Università degli Studi di Milano; Milan Italy

3. Department of Oncology and Hematology; Università degli Studi di Milano; Milan Italy

4. Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine; University of Insubria; Varese Italy

Publisher

Wiley

Subject

Hematology

Reference59 articles.

1. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med.,2012

2. Ruxolitinib versus standard therapy for the treatment of polycythemia vera;Vannucchi;N Engl J Med.,2015

3. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med.,2012

4. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial;Verstovsek;J Hematol Oncol.,2017

5. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms;Quintas-Cardama;Blood.,2010

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Applications of Biological Therapy for Latent Infections: Benefits and Risks;International Journal of Molecular Sciences;2024-08-24

3. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

4. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN);Annals of Hematology;2024-07-05

5. Overview of infectious complications among CAR T- cell therapy recipients;Frontiers in Oncology;2024-07-03